

Appendix Table F60. Results from VIBRANT trial³⁹⁵

Outcome	Dose	Relative risk 95% CI)	Absolute risk difference (95% CI)	Number needed to treat (95% CI)	Attributable events (95% CI)
BSW: benefit-much	5 -10mg daily	1.78 (1.48; 2.14)	0.222 (0.155; 0.290)	4 (3; 6)	222 (155; 290)
BSW: satisfaction-yes	5 -10mg daily	1.42 (1.26; 1.61)	0.207 (0.139; 0.275)	5 (4; 7)	207 (139; 275)
BSW: willingness to continue-yes	5 -10mg daily	1.39 (1.23; 1.57)	0.192 (0.123; 0.260)	5 (4; 8)	192 (123; 260)
PPBC score: None	5 -10mg daily	1.32 (0.88; 1.98)	0.030 (-0.014; 0.074)		
PPBC score: Very minor	5 -10mg daily	1.46 (1.10; 1.94)	0.079 (0.021; 0.136)	13 (7; 47)	79 (21; 136)
Discontinuation	10mg daily	0.84 (0.39; 1.81)	-0.011 (-0.057; 0.036)		
	5mg daily	0.63 (0.27; 1.46)	-0.031 (-0.089; 0.027)		
BSW: benefit-little	5 -10mg daily	0.88 (0.67; 1.15)	-0.028 (-0.087; 0.030)		
BSW: benefit-none	5 -10mg daily	0.46 (0.34; 0.61)	-0.164 (-0.221; -0.106)	-6 (-9; -5)	-164 (-221; -106)
BSW: satisfaction-no	5 -10mg daily	0.51 (0.39; 0.66)	-0.167 (-0.227; -0.106)	-6 (-9; -4)	-167 (-227; -106)
BSW: willingness to continue-no	5 -10mg daily	0.55 (0.43; 0.71)	-0.151 (-0.212; -0.090)	-7 (-11; -5)	-151 (-212; -90)
PPBC score: Severe	5 -10mg daily	0.42 (0.27; 0.64)	-0.095 (-0.140; -0.050)	-11 (-20; -7)	-95 (-140; -50)
PPBC score: Many severe	5 -10mg daily	0.78 (0.36; 1.69)	-0.008 (-0.033; 0.017)		
Dry mouth	5 -10mg daily	5.61 (2.80; 11.23)	0.109 (0.072; 0.146)	9 (7; 14)	109 (72; 146)
Constipation	5 -10mg daily	4.38 (1.95; 9.83)	0.062 (0.032; 0.092)	16 (11; 32)	62 (32; 92)
Dry eye	5 -10mg daily	5.94 (0.72; 49.09)	0.013 (0.000; 0.026)		
Dyspepsia	5 -10mg daily	10.89 (0.60; 196.20)	0.013 (0.001; 0.025)	77 (40; 1616)	13 (1; 25)
Fatigue	5 -10mg daily	2.47 (0.48; 12.67)	0.008 (-0.006; 0.021)		
Nausea	5 -10mg daily	0.66 (0.19; 2.32)	-0.005 (-0.021; 0.011)		
Blurred vision	5 -10mg daily	0.79 (0.21; 2.93)	-0.003 (-0.018; 0.013)		
Headache	5 -10mg daily	0.59 (0.14; 2.47)	-0.005 (-0.020; 0.009)		